Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
Text Size

Health News

Clot-Buster Doesn't Raise Bleeding Risk in Warfarin Patients: Study

Clot-Buster Doesn't Raise Bleeding Risk in Warfarin Patients: Study


THURSDAY, May 10 (HealthDay News) -- Tissue plasminogen activator (tPA), a drug used to combat clots in stroke patients, does not increase the risk of dangerous bleeding in patients also taking the blood thinner warfarin, new research found.

The study included information on more than 23,000 ischemic stroke patients treated with tPA at more than 1,200 U.S. hospitals. Ischemic stroke, the most common type of brain attack, is caused by a blocked blood vessel to the brain. The clot-busting drug tPA is sold under the brand name Activase and the generic name alteplase.

In the study, about 8 percent of the stroke patients were taking the anticoagulant warfarin (Coumadin) before hospital admission.

The researchers found little difference in the risk of severe bleeding due to a brain hemorrhage in patients who received tPA while on warfarin versus those not taking the blood-thinning drug. The study also found no major differences in the patients' risks of tPA-related complications or in-hospital death after tPA.

The research was scheduled to be presented on Thursday at the American Heart Association's Quality of Care and Outcomes Research meeting in Atlanta.

"Although it's the only drug approved by the U.S. Food and Drug Administration to treat acute ischemic stroke, tPA is underused among patients on home warfarin therapy mainly because of the fear that it will cause bleeding," study lead author Dr. Ying Xian, a research fellow at Duke Clinical Research Institute in Durham, N.C., said in a heart association news release.

The researchers noted that the patients taking warfarin were usually older, had more illnesses and had more severe strokes than those not on warfarin.

"Our study suggests tPA is not associated with excessive bleeding or death among warfarin patients when used according to American Heart Association/American Stroke Association guidelines," Xian said.

And, the researcher added, tPA "has been shown to minimize brain damage and disability from stroke and should not be withheld from these patients."

The study authors pointed out that they didn't measure functional, neurological or long-term results of tPA treatment.

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Stroke Association has more about treatments for stroke.

Copyright © 2012 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.


Latest News

Crouse Hospital Appoints Chief Information Officer
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >